Trial Outcomes & Findings for Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users (NCT NCT04881942)
NCT ID: NCT04881942
Last Updated: 2024-07-30
Results Overview
Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
COMPLETED
NA
35 participants
Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)
2024-07-30
Participant Flow
35 subjects (including alternates) used at least one test product during the Day -1 Trial. One subject discontinued from the study before randomization; 2 alternates were discontinued prior to randomization once the enrollment goal of 32 subjects was met. Therefore, a total of 32 subjects were randomized into the study. The 3 subjects who were discontinued prior to randomization constitute the "Day -1 Trial" group and are included in the Safety Population for AE reporting, and Baseline data.
Participant milestones
| Measure |
ABDC
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4
|
BCAD
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4
|
CDBA
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4
|
DACB
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4
|
Day -1 Trial
Subjects who used at least one test product during the Visit 2, Day -1 product trial, but were not subsequently randomized.
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
8
|
8
|
8
|
8
|
3
|
|
Overall Study
Completed Day 1 Product Use
|
8
|
8
|
8
|
8
|
0
|
|
Overall Study
Completed Day 2 Product Use
|
8
|
8
|
8
|
8
|
0
|
|
Overall Study
Completed Day 3 Product Use
|
8
|
8
|
8
|
8
|
0
|
|
Overall Study
Completed Day 4 Product Use
|
8
|
8
|
8
|
8
|
0
|
|
Overall Study
COMPLETED
|
8
|
8
|
8
|
8
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
3
|
Reasons for withdrawal
| Measure |
ABDC
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4
|
BCAD
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4
|
CDBA
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4
|
DACB
Subjects administered 2 menthol and 2 non-menthol test e-vapor products:
Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4
|
Day -1 Trial
Subjects who used at least one test product during the Visit 2, Day -1 product trial, but were not subsequently randomized.
|
|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Alternates
|
0
|
0
|
0
|
0
|
2
|
Baseline Characteristics
Not all participants were asked to respond due to skip logics.
Baseline characteristics by cohort
| Measure |
ABDC
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:
Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4
|
BCAD
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:
Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4
|
CDBA
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:
Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4
|
DACB
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products:
Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4
|
Day-1 Trial
n=3 Participants
Subjects who used at least one test product during the Visit 2, Day -1 product trial, but were not subsequently randomized
|
Total
n=35 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Smoking Frequency in past 30 days
Missing Response / Skip Logics
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
35 Participants
n=35 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Age, Continuous
|
35.3 Years
STANDARD_DEVIATION 12.02 • n=8 Participants
|
34.9 Years
STANDARD_DEVIATION 12.49 • n=8 Participants
|
41.1 Years
STANDARD_DEVIATION 15.95 • n=8 Participants
|
35.4 Years
STANDARD_DEVIATION 11.73 • n=8 Participants
|
37.7 Years
STANDARD_DEVIATION 14.22 • n=3 Participants
|
36.7 Years
STANDARD_DEVIATION 12.68 • n=35 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
15 Participants
n=35 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
2 Participants
n=3 Participants
|
20 Participants
n=35 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
31 Participants
n=35 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Race (NIH/OMB)
Black or African American
|
6 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=3 Participants
|
24 Participants
n=35 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
10 Participants
n=35 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Annual Household Income
<$20,000
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
18 Participants
n=35 Participants
|
|
Annual Household Income
$20,000-$29,999
|
0 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
8 Participants
n=35 Participants
|
|
Annual Household Income
$30,000-$39,999
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Annual Household Income
$40,000-$49,999
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Annual Household Income
$50,000-$59,999
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Annual Household Income
$75,000-$99,999
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Annual Household Income
No answer
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Education
9-11 years
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Education
12 years or GED
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
13 Participants
n=35 Participants
|
|
Education
Some college
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
14 Participants
n=35 Participants
|
|
Education
College graduate
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
4 Participants
n=35 Participants
|
|
Education
Other
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Education
No answer
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Height
|
168.6 cm
STANDARD_DEVIATION 8.16 • n=8 Participants
|
174.6 cm
STANDARD_DEVIATION 7.99 • n=8 Participants
|
170.7 cm
STANDARD_DEVIATION 10.28 • n=8 Participants
|
172.7 cm
STANDARD_DEVIATION 8.40 • n=8 Participants
|
177.7 cm
STANDARD_DEVIATION 22.64 • n=3 Participants
|
172.1 cm
STANDARD_DEVIATION 10.04 • n=35 Participants
|
|
Weight
|
80.4 kg
STANDARD_DEVIATION 17.90 • n=8 Participants
|
91.3 kg
STANDARD_DEVIATION 21.44 • n=8 Participants
|
82.8 kg
STANDARD_DEVIATION 11.91 • n=8 Participants
|
76.0 kg
STANDARD_DEVIATION 19.60 • n=8 Participants
|
77.1 kg
STANDARD_DEVIATION 11.46 • n=3 Participants
|
82.1 kg
STANDARD_DEVIATION 17.56 • n=35 Participants
|
|
Body Mass Index (BMI)
|
28.16 kg/m²
STANDARD_DEVIATION 5.535 • n=8 Participants
|
29.89 kg/m²
STANDARD_DEVIATION 6.014 • n=8 Participants
|
28.48 kg/m²
STANDARD_DEVIATION 3.699 • n=8 Participants
|
25.26 kg/m²
STANDARD_DEVIATION 5.177 • n=8 Participants
|
24.97 kg/m²
STANDARD_DEVIATION 6.035 • n=3 Participants
|
27.69 kg/m²
STANDARD_DEVIATION 5.254 • n=35 Participants
|
|
Employment Status
Wage Earner
|
2 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
2 Participants
n=3 Participants
|
16 Participants
n=35 Participants
|
|
Employment Status
Self-Employed
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
5 Participants
n=35 Participants
|
|
Employment Status
Unemployed > 1 year
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Employment Status
Unemployed < 1 year
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Employment Status
Homemaker
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Employment Status
Student
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Employment Status
Retired
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Employment Status
Unable to work
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Military Experience
Active Duty
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Military Experience
Discharged More Than 1 Year Ago
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Military Experience
Never in military
|
6 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
31 Participants
n=35 Participants
|
|
Military Experience
No answer
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Marital Status
Single
|
5 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
2 Participants
n=3 Participants
|
23 Participants
n=35 Participants
|
|
Marital Status
Married/Partnered
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
5 Participants
n=35 Participants
|
|
Marital Status
Divorced/Separated/Widowed
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
4 Participants
n=35 Participants
|
|
Marital Status
No answer
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Sexual Identity
Heterosexual or Straight
|
7 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
33 Participants
n=35 Participants
|
|
Sexual Identity
No answer
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Previous Cigarette Usage
Yes
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
34 Participants
n=35 Participants
|
|
Previous Cigarette Usage
No
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
100 or more lifetime cigarettes
Yes
|
6 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
32 Participants
n=35 Participants
|
|
100 or more lifetime cigarettes
No
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
100 or more lifetime cigarettes
Missing Response / Skip Logics
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Smoke on a regular basis
Yes
|
7 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
33 Participants
n=35 Participants
|
|
Smoke on a regular basis
No
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Smoke on a regular basis
Missing Response / Skip Logics
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Length of Consistent Smoking
|
9.9 Years
STANDARD_DEVIATION 8.23 • n=7 Participants • Not all participants were asked to respond due to skip logics.
|
12.7 Years
STANDARD_DEVIATION 9.69 • n=7 Participants • Not all participants were asked to respond due to skip logics.
|
19.1 Years
STANDARD_DEVIATION 14.70 • n=8 Participants • Not all participants were asked to respond due to skip logics.
|
13.0 Years
STANDARD_DEVIATION 13.90 • n=8 Participants • Not all participants were asked to respond due to skip logics.
|
13.7 Years
STANDARD_DEVIATION 7.09 • n=3 Participants • Not all participants were asked to respond due to skip logics.
|
13.8 Years
STANDARD_DEVIATION 11.57 • n=33 Participants • Not all participants were asked to respond due to skip logics.
|
|
Smoking Frequency in past 30 days
Every Day
|
4 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
13 Participants
n=35 Participants
|
|
Smoking Frequency in past 30 days
Some Days
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
9 Participants
n=35 Participants
|
|
Smoking Frequency in past 30 days
Not at all
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
11 Participants
n=35 Participants
|
|
Daily Cigarette Use
|
9.7 number of cigarettes
STANDARD_DEVIATION 5.96 • n=6 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
|
9.0 number of cigarettes
STANDARD_DEVIATION 4.30 • n=5 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
|
9.6 number of cigarettes
STANDARD_DEVIATION 5.55 • n=5 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
|
2.8 number of cigarettes
STANDARD_DEVIATION 2.22 • n=4 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
|
14.0 number of cigarettes
STANDARD_DEVIATION 8.49 • n=2 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
|
8.6 number of cigarettes
STANDARD_DEVIATION 5.64 • n=22 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
|
|
Menthol Cigarettes Regularly
Yes
|
6 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
2 Participants
n=3 Participants
|
19 Participants
n=35 Participants
|
|
Menthol Cigarettes Regularly
No
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=35 Participants
|
|
Menthol Cigarettes Regularly
Missing Response / Skip Logics
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
13 Participants
n=35 Participants
|
|
Daily Smoking
Yes
|
4 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
16 Participants
n=35 Participants
|
|
Daily Smoking
No
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
6 Participants
n=35 Participants
|
|
Daily Smoking
Missing Response / Skip Logics
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
13 Participants
n=35 Participants
|
|
Previously Quit Smoking
Yes
|
2 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
7 Participants
n=35 Participants
|
|
Previously Quit Smoking
No
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
15 Participants
n=35 Participants
|
|
Previously Quit Smoking
Missing Response / Skip Logics
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
13 Participants
n=35 Participants
|
|
Quit Smoking Completely
Yes
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
10 Participants
n=35 Participants
|
|
Quit Smoking Completely
No
|
6 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
23 Participants
n=35 Participants
|
|
Quit Smoking Completely
Missing Response / Skip Logics
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Current Quit Smoking Duration
< 6 months
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Current Quit Smoking Duration
> 6 months
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
9 Participants
n=35 Participants
|
|
Current Quit Smoking Duration
Missing Response / Skip Logics
|
7 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
25 Participants
n=35 Participants
|
|
Previous E-Cigarette Usage
Yes
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
35 Participants
n=35 Participants
|
|
Previous E-Cigarette Usage
No
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 1
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
4 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 2
|
1 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
8 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 3
|
4 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
17 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 1 + Type 2
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 1 + Type 3
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 2 + Type 3
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=35 Participants
|
|
Type of e-Cigarette and e-Vapor Product Use
Type 1 + Type 2 + Type 3
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Number of Days of e-cigarette Use in Past Week
|
6.0 days
STANDARD_DEVIATION 1.20 • n=8 Participants
|
6.6 days
STANDARD_DEVIATION 0.74 • n=8 Participants
|
6.6 days
STANDARD_DEVIATION 1.06 • n=8 Participants
|
6.8 days
STANDARD_DEVIATION 0.46 • n=8 Participants
|
7.0 days
STANDARD_DEVIATION 0.00 • n=3 Participants
|
6.5 days
STANDARD_DEVIATION 0.89 • n=35 Participants
|
|
30 Day Disposable E-Cigarette/Cartridge Count
|
0.6 E-Cigarettes/Cartridges
STANDARD_DEVIATION 0.74 • n=8 Participants
|
0.6 E-Cigarettes/Cartridges
STANDARD_DEVIATION 0.74 • n=8 Participants
|
0.3 E-Cigarettes/Cartridges
STANDARD_DEVIATION 0.46 • n=8 Participants
|
0.9 E-Cigarettes/Cartridges
STANDARD_DEVIATION 1.64 • n=8 Participants
|
3.7 E-Cigarettes/Cartridges
STANDARD_DEVIATION 5.51 • n=3 Participants
|
0.9 E-Cigarettes/Cartridges
STANDARD_DEVIATION 1.85 • n=35 Participants
|
|
Milliliters of E-Liquid/day in last 30 Days
|
3.6 ml/day
STANDARD_DEVIATION 6.72 • n=8 Participants
|
2.1 ml/day
STANDARD_DEVIATION 3.31 • n=8 Participants
|
4.6 ml/day
STANDARD_DEVIATION 6.70 • n=8 Participants
|
3.5 ml/day
STANDARD_DEVIATION 3.12 • n=8 Participants
|
2.0 ml/day
STANDARD_DEVIATION 3.46 • n=3 Participants
|
3.3 ml/day
STANDARD_DEVIATION 4.94 • n=35 Participants
|
|
e-Cigarette Length of Use
|
17.8 months
STANDARD_DEVIATION 10.98 • n=8 Participants
|
14.5 months
STANDARD_DEVIATION 6.02 • n=8 Participants
|
22.5 months
STANDARD_DEVIATION 15.96 • n=8 Participants
|
17.8 months
STANDARD_DEVIATION 8.70 • n=8 Participants
|
11.3 months
STANDARD_DEVIATION 11.02 • n=3 Participants
|
17.5 months
STANDARD_DEVIATION 10.90 • n=35 Participants
|
|
e-Cigarette Use Frequency in Past 30 Days
Every Day
|
4 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
28 Participants
n=35 Participants
|
|
e-Cigarette Use Frequency in Past 30 Days
Some Days
|
4 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
7 Participants
n=35 Participants
|
|
e-Cigarette Use Frequency in Past 30 Days
Not at all
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Quit E-Cigarettes in Last Year
Yes
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=35 Participants
|
|
Quit E-Cigarettes in Last Year
No
|
7 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
34 Participants
n=35 Participants
|
|
Plan to Quit Smoking
Yes
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
4 Participants
n=35 Participants
|
|
Plan to Quit Smoking
No
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
20 Participants
n=35 Participants
|
|
Plan to Quit Smoking
Missing Response / Skip Logics
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
11 Participants
n=35 Participants
|
|
Plan to Quit E-Cigarettes
Yes
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=35 Participants
|
|
Plan to Quit E-Cigarettes
No
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
3 Participants
n=3 Participants
|
35 Participants
n=35 Participants
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Nicotine Residue Summary Statistics by Test-Product Group
|
182.8 Micrograms
Standard Deviation 253.88
|
87.1 Micrograms
Standard Deviation 120.11
|
192.3 Micrograms
Standard Deviation 268.53
|
174.1 Micrograms
Standard Deviation 208.64
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Nicotine Residue Summary Statistics by Test-Product Group
|
0.9 Micrograms
Standard Deviation 0.69
|
0.9 Micrograms
Standard Deviation 0.66
|
0.9 Micrograms
Standard Deviation 0.66
|
0.9 Micrograms
Standard Deviation 0.70
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Nicotine Summary Statistics by Test Product Group
|
181.8 Micrograms
Standard Deviation 254.23
|
86.1 Micrograms
Standard Deviation 120.40
|
191.4 Micrograms
Standard Deviation 268.78
|
173.1 Micrograms
Standard Deviation 208.93
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Glycerin Residue Summary Statistics by Test-Product Group
|
5682.4 Micrograms
Standard Deviation 5156.04
|
5964.4 Micrograms
Standard Deviation 5029.33
|
5707.3 Micrograms
Standard Deviation 5015.41
|
6516.6 Micrograms
Standard Deviation 5387.80
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Glycerin Residue Summary Statistics by Test-Product Group
|
10.9 Micrograms
Standard Deviation 2.65
|
15.4 Micrograms
Standard Deviation 16.49
|
11.1 Micrograms
Standard Deviation 5.01
|
15.4 Micrograms
Standard Deviation 16.53
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Glycerin Summary Statistics by Test Product Group
|
5671.5 Micrograms
Standard Deviation 5155.84
|
5949.0 Micrograms
Standard Deviation 5033.63
|
5696.2 Micrograms
Standard Deviation 5015.99
|
6501.2 Micrograms
Standard Deviation 5385.54
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Menthol Residue Summary Statistics by Test-Product Group
|
31.3 Micrograms
Standard Deviation 15.12
|
0.4 Micrograms
Standard Deviation 0.13
|
0.4 Micrograms
Standard Deviation 0.08
|
22.1 Micrograms
Standard Deviation 9.99
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Menthol Residue Summary Statistics by Test-Product Group
|
0.4 Micrograms
Standard Deviation 0.08
|
0.5 Micrograms
Standard Deviation 0.42
|
0.4 Micrograms
Standard Deviation 0.08
|
0.4 Micrograms
Standard Deviation 0.08
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Menthol Summary Statistics by Test Product Group
|
30.9 Micrograms
Standard Deviation 15.12
|
-0.1 Micrograms
Standard Deviation 0.30
|
0.0 Micrograms
Standard Deviation 0.00
|
21.7 Micrograms
Standard Deviation 9.98
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Propylene Glycol Residue Summary Statistics by Test-Product Group
|
2675.8 Micrograms
Standard Deviation 3794.98
|
1697.6 Micrograms
Standard Deviation 2351.62
|
1047.7 Micrograms
Standard Deviation 1497.14
|
3343.4 Micrograms
Standard Deviation 4090.27
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Propylene Glycol Residue Summary Statistics by Test-Product Group
|
14.6 Micrograms
Standard Deviation 0.66
|
14.9 Micrograms
Standard Deviation 1.54
|
14.9 Micrograms
Standard Deviation 2.18
|
15.4 Micrograms
Standard Deviation 2.97
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Propylene Glycol Summary Statistics by Test Product Group
|
2661.2 Micrograms
Standard Deviation 3795.07
|
1682.7 Micrograms
Standard Deviation 2351.82
|
1032.8 Micrograms
Standard Deviation 1497.42
|
3328.0 Micrograms
Standard Deviation 4090.90
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Formaldehyde Residue Summary Statistics by Test-Product Group
|
1.2 Micrograms
Standard Deviation 0.85
|
1.0 Micrograms
Standard Deviation 0.74
|
1.1 Micrograms
Standard Deviation 0.95
|
1.3 Micrograms
Standard Deviation 0.92
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Formaldehyde Residue Summary Statistics by Test-Product Group
|
1.0 Micrograms
Standard Deviation 0.79
|
0.8 Micrograms
Standard Deviation 0.66
|
0.8 Micrograms
Standard Deviation 0.63
|
1.0 Micrograms
Standard Deviation 0.79
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Formaldehyde Summary Statistics by Test Product Group
|
0.27 Micrograms
Standard Deviation 0.329
|
0.19 Micrograms
Standard Deviation 0.241
|
0.33 Micrograms
Standard Deviation 0.650
|
0.35 Micrograms
Standard Deviation 0.326
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Acetaldehyde Residue Summary Statistics by Test-Product Group
|
0.50 Micrograms
Standard Deviation 0.000
|
0.50 Micrograms
Standard Deviation 0.000
|
0.50 Micrograms
Standard Deviation 0.000
|
0.50 Micrograms
Standard Deviation 0.000
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Acetaldehyde Residue Summary Statistics by Test-Product Group
|
0.50 Micrograms
Standard Deviation 0.000
|
0.50 Micrograms
Standard Deviation 0.000
|
0.50 Micrograms
Standard Deviation 0.000
|
0.50 Micrograms
Standard Deviation 0.000
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Acetaldehyde Summary Statistics by Test Product Group
|
0.0 Micrograms
Standard Deviation 0.00
|
0.0 Micrograms
Standard Deviation 0.00
|
0.0 Micrograms
Standard Deviation 0.00
|
0.0 Micrograms
Standard Deviation 0.00
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Acrolein Residue Summary Statistics by Test-Product Group
|
0.63 Micrograms
Standard Error 0.000
|
0.63 Micrograms
Standard Error 0.000
|
0.63 Micrograms
Standard Error 0.000
|
0.63 Micrograms
Standard Error 0.000
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Sham Acrolein Residue Summary Statistics by Test-Product Group
|
0.6 Micrograms
Standard Error 0.00
|
0.6 Micrograms
Standard Error 0.00
|
0.6 Micrograms
Standard Error 0.00
|
0.6 Micrograms
Standard Error 0.00
|
PRIMARY outcome
Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Sham-Corrected Acrolein Summary Statistics by Test Product Group
|
0.0 Micrograms
Standard Error 0.00
|
0.0 Micrograms
Standard Error 0.00
|
0.0 Micrograms
Standard Error 0.00
|
0.0 Micrograms
Standard Error 0.00
|
SECONDARY outcome
Timeframe: Samples collected during the approximately 1 hour controlled exhaled breath product use session on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Difference in recorded weight of Sample 1, measured in grams, collected before and after product use in Exhaled Breath Sessions. Sample 1 was used to collect propylene glycol, glycerin, nicotine and menthol, and was collected approximately 1 hour before Sample 2.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Cartridge Weight (g) Change Summary Statistics for Sample 1 (Propylene Glycol, Glycerin, Nicotine, Menthol) by Test Product in the Exhaled-Breath Sessions
|
0.0367 Grams
Standard Deviation 0.012324
|
0.0352 Grams
Standard Deviation 0.008701
|
0.0337 Grams
Standard Deviation 0.011374
|
0.0402 Grams
Standard Deviation 0.012596
|
SECONDARY outcome
Timeframe: Samples collected during the approximately 1 hour controlled exhaled breath product use session on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)Difference in recorded weight of Sample 2, measured in grams, collected before and after product use in Exhaled Breath Sessions, Sample 2 was used to collect formaldehyde, acetaldehyde and acrolein, and was collected approximately 1 hour after Sample 1.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Cartridge Weight (g) Change Summary Statistics for Sample 2 (Formaldehyde, Acetaldehyde, Acrolein) by Test Product in the Exhaled-Breath Sessions
|
0.0379 Grams
Standard Deviation 0.012395
|
0.0356 Grams
Standard Deviation 0.011530
|
0.0363 Grams
Standard Deviation 0.011936
|
0.0412 Grams
Standard Deviation 0.014581
|
SECONDARY outcome
Timeframe: Samples were collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Difference in recorded weight (measured in grams) by test product, per subject, collected before and after product use in ad libitum sessions
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Summary Statistics of Total Cartridge Weight Change by Test Product, Per Subject, During the Ad Libitum-Use Sessions
|
0.418 Grams
Standard Deviation 0.33120
|
0.534 Grams
Standard Deviation 0.43562
|
0.406 Grams
Standard Deviation 0.32699
|
0.469 Grams
Standard Deviation 0.36765
|
SECONDARY outcome
Timeframe: Samples were collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Change in cartridge weight (measured in grams) as measured before and after a 12-hour ad-libitum use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=35 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=42 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=39 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=39 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
|
0.369 Grams
Standard Deviation 0.23418
|
0.428 Grams
Standard Deviation 0.26613
|
0.310 Grams
Standard Deviation 0.22996
|
0.398 Grams
Standard Deviation 0.25131
|
|
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
|
0.383 Grams
Standard Deviation 0.21158
|
0.351 Grams
Standard Deviation 0.25264
|
0.381 Grams
Standard Deviation 0.24206
|
0.309 Grams
Standard Deviation 0.26700
|
|
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
|
—
|
0.293 Grams
Standard Deviation 0.06010
|
0.812 Grams
Standard Deviation 0
|
0.444 Grams
Standard Deviation 0
|
|
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
|
0.370 Grams
Standard Deviation 0.22882
|
0.407 Grams
Standard Deviation 0.25716
|
0.333 Grams
Standard Deviation 0.24023
|
0.385 Grams
Standard Deviation 0.24910
|
SECONDARY outcome
Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Number of puffs, by test product, per subject, taken during 12-hour ad libitum product use session
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=31 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Summary Statistics of Puff Count by Test Product During the Ad Libitum-Use Sessions
|
242.839 puffs
Standard Deviation 194.6732
|
292.375 puffs
Standard Deviation 204.2479
|
239.000 puffs
Standard Deviation 164.4613
|
246.375 puffs
Standard Deviation 170.3419
|
SECONDARY outcome
Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Seconds per puff taken, by test product, per subject, during 12-hour ad libitum product use session
Outcome measures
| Measure |
e-Vapor Product D
n=30 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=31 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=30 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=31 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Average Puff Duration by Test Product During the Ad Libitum-Use Sessions
|
2.209 seconds per puff
Standard Deviation 0.75672
|
2.471 seconds per puff
Standard Deviation 1.01786
|
2.373 seconds per puff
Standard Deviation 1.10711
|
2.249 seconds per puff
Standard Deviation 0.89143
|
SECONDARY outcome
Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Total seconds puffing by test product, per subject, taken during 12-hour ad libitum product use session
Outcome measures
| Measure |
e-Vapor Product D
n=30 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=31 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=30 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=31 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Puff Duration by Test Product During the Ad Libitum-Use Sessions
|
517.733 Seconds
Standard Deviation 386.5348
|
726.028 Seconds
Standard Deviation 551.0662
|
589.204 Seconds
Standard Deviation 435.7242
|
575.807 Seconds
Standard Deviation 442.4253
|
SECONDARY outcome
Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Total cartridges used by test product, per subject, taken during 12-hour ad libitum product use session
Outcome measures
| Measure |
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Cartridges Used by Test Product During the Ad Libitum-Use Sessions
|
1.129 Cartridges
Standard Deviation 0.34078
|
1.313 Cartridges
Standard Deviation 0.59229
|
1.219 Cartridges
Standard Deviation 0.49084
|
1.219 Cartridges
Standard Deviation 0.49084
|
SECONDARY outcome
Timeframe: Data was collected at the end of the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Visual Analog Scale (VAS) measuring self-reported response to "Use the product again" questionnaire was collected after each product use session. The questionnaire consists of a single question ("If given the opportunity, I would want to use this product again"). Participants indicated their willingness to use the product again by pointing to a line measuring 100mm, with scores measured from left to right and ranging between 0 to 100 mm. Scores closer to the right, and thus higher on the scale, indicated a greater willingness to utilize the product again. Raw scores were converted to a binary score as follows: VAS scores \< 50 mm ≈ unwillingness to use the product again, and VAS scores ≥ 50 mm ≈ willingness to use product again.
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Summary of Binary VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Want to Use
|
28 Participants
|
29 Participants
|
29 Participants
|
27 Participants
|
|
Summary of Binary VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Do not Want to Use
|
4 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: Data was collected at the end of the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Visual Analog Scale (VAS) measuring self-reported response to willingness to use study product again. Questionnaire was collected after each product use session. Questionnaire consists of a single question ("If given the opportunity, I would want to use this product again") with VAS response range from "Definitely Would Not" to "Don't Care" to "Definitely Would". Participants indicated their willingness to use the product again by pointing to a line measuring 100mm, with scores measured from left to right and ranging between 0 to 100 mm. Scores closer to the right, and thus higher on the scale, indicated a greater willingness to utilize the product again. The raw scores were then converted to a binary, "unwilling" vs. "willing" to use response. Additionally, a 3-level ordinal response was computed using "unwilling" (VAS \< 50 mm), "don't care" (VAS = 50 mm), and "willing" (VAS \> 50 mm).
Outcome measures
| Measure |
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Summary of Ordinal VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Want to Use
|
28 Participants
|
29 Participants
|
29 Participants
|
26 Participants
|
|
Summary of Ordinal VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Don't Care
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Summary of Ordinal VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Do Not Want to Use
|
4 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Puff Count by Test Product (Pooled Over Cartridges) during 12-hour ad-libitum-use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=35 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=42 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=37 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=39 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
|
220.032 Puffs
Standard Deviation 141.3675
|
247.156 Puffs
Standard Deviation 146.7016
|
197.065 Puffs
Standard Deviation 147.5464
|
217.969 Puffs
Standard Deviation 143.7912
|
|
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
|
176.750 Puffs
Standard Deviation 193.3190
|
164.250 Puffs
Standard Deviation 121.5680
|
195.600 Puffs
Standard Deviation 98.79929
|
117.333 Puffs
Standard Deviation 130.9712
|
|
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
|
—
|
66.500 Puffs
Standard Deviation 27.57716
|
322.000 Puffs
Standard Deviation 0
|
205.000 Puffs
Standard Deviation 0
|
|
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
|
215.086 Puffs
Standard Deviation 145.3491
|
222.762 Puffs
Standard Deviation 145.3878
|
200.243 Puffs
Standard Deviation 140.1773
|
202.154 Puffs
Standard Deviation 143.0770
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Average puff duration (measured in seconds) by Test Product (Pooled Over Cartridges) during 12-hour ad-libitum-use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=34 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=41 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=36 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=37 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
|
2.194 Seconds
Standard Deviation 0.73162
|
2.487 Seconds
Standard Deviation 1.05031
|
2.369 Seconds
Standard Deviation 1.10274
|
2.275 Seconds
Standard Deviation 0.92685
|
|
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
|
2.685 Seconds
Standard Deviation 1.32845
|
2.674 Seconds
Standard Deviation 1.13172
|
3.111 Seconds
Standard Deviation 1.52758
|
3.004 Seconds
Standard Deviation 0.89069
|
|
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
|
—
|
4.761 Seconds
Standard Deviation 0.06038
|
3.598 Seconds
Standard Deviation 0
|
3.330 Seconds
Standard Deviation 0
|
|
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
|
2.252 Seconds
Standard Deviation 0.81028
|
2.634 Seconds
Standard Deviation 1.13792
|
2.506 Seconds
Standard Deviation 1.17333
|
2.402 Seconds
Standard Deviation 0.94449
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Total Puff Duration (measured in seconds) by Test Product (pooled over cartridges) during 12-hour ad-libitum-use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=34 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=41 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=36 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=37 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
|
—
|
315.777 Seconds
Standard Deviation 127.2806
|
1158.612 Seconds
Standard Deviation 0
|
682.752 Seconds
Standard Deviation 0
|
|
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
|
456.823 Seconds
Standard Deviation 278.4626
|
548.948 Seconds
Standard Deviation 352.5085
|
491.003 Seconds
Standard Deviation 309.3294
|
482.433 Seconds
Standard Deviation 288.8387
|
|
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
|
463.815 Seconds
Standard Deviation 273.8106
|
597.673 Seconds
Standard Deviation 366.5793
|
455.996 Seconds
Standard Deviation 299.0212
|
486.874 Seconds
Standard Deviation 274.7173
|
|
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
|
404.380 Seconds
Standard Deviation 352.2326
|
418.433 Seconds
Standard Deviation 293.8095
|
567.524 Seconds
Standard Deviation 247.0947
|
414.832 Seconds
Standard Deviation 411.0123
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Change in cartridge weight (measured in grams) as measured before and after a 12-hour ad-libitum use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=10 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=7 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Weight Change by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
|
0.656 Grams
Standard Deviation 0.15309
|
0.623 Grams
Standard Deviation 0.24705
|
0.315 Grams
Standard Deviation 0.18197
|
0.664 Grams
Standard Deviation 0.19375
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Average puff duration (measured in seconds) by Test Product, per completed cartridge, during a 12-hour ad-libitum use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=8 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=6 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Average Puff Duration by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
|
2.491 Seconds
Standard Deviation 0.60612
|
3.033 Seconds
Standard Deviation 1.30359
|
3.004 Seconds
Standard Deviation 1.27635
|
3.019 Seconds
Standard Deviation 0.93719
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Puff count by Test Product, per completed cartridge, during a 12-hour ad-libitum use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=10 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=7 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Puff Count by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
|
311.400 Puffs
Standard Deviation 171.0111
|
298.300 Puffs
Standard Deviation 155.1444
|
159.714 Puffs
Standard Deviation 108.9567
|
280.000 Puffs
Standard Deviation 137.6311
|
SECONDARY outcome
Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session
Total Puff Duration (measured in seconds) by Test Product, per completed cartridge, during a 12-hour ad-libitum use session of the product.
Outcome measures
| Measure |
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
e-Vapor Product A
n=10 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=7 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
|
|---|---|---|---|---|
|
Total Puff Duration by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
|
729.328 Seconds
Standard Deviation 317.4452
|
814.728 Seconds
Standard Deviation 350.9879
|
432.943 Seconds
Standard Deviation 240.6142
|
766.922 Seconds
Standard Deviation 307.3669
|
Adverse Events
e-Vapor Product A
e-Vapor Product B
e-Vapor Product C
e-Vapor Product D
Day -1 Product Trial Non-randomized Subjects
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
e-Vapor Product A
n=32 participants at risk
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\])
e-Vapor Product A: e-Vapor product
|
e-Vapor Product B
n=32 participants at risk
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\])
e-Vapor Product B: e-Vapor product
|
e-Vapor Product C
n=32 participants at risk
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\])
e-Vapor Product C: e-Vapor product
|
e-Vapor Product D
n=32 participants at risk
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\])
e-Vapor Product D: e-Vapor product
|
Day -1 Product Trial Non-randomized Subjects
n=3 participants at risk
Subjects who were not randomized after participating in the Day -1 Product Trial using all study products including:
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\] e-Vapor Product C: e-Vapor product Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
|
|---|---|---|---|---|---|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Nervous system disorders
Headache
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Nervous system disorders
Dizziness
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Gastrointestinal disorders
Oral Discomfort
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
33.3%
1/3 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
|
Additional Information
Jeffery Edmiston, Functional Director Clinical Research
Altria
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place